Pieris Pharmaceuticals, Inc. (PIRS)
PIRSPrice: $13.6
Fair Value: 🔒
🔒score
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human protein... more
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops ant... more
Description
Shares
| Market Cap | $17.96M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Stephen S. Yoder |
| IPO Date | 2015-01-02 | CAGR | — |
| Employees | 46 | Website | www.pieris.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PIRS chart loading...
Fundamentals
Technicals
| Enterprise Value | $79.88M | P/E Ratio | -1.12 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | -338.78 | P/B Ratio | 3.15 |
| P/CF Ratio | -7.43 | P/FCF Ratio | -0.89 |
| EPS | $-12.11 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -100.25% | Gross Margin | -21.02% |
| Operating Margin | -178.87% | Profit Margin | 502.04% |
| ROE | -0.58% | ROA | -0.36% |
| ROCE | 0.15% | Current Ratio | 7.67 |
| Quick Ratio | 7.67 | Cash Ratio | 7.32 |
| Debt/Equity | — | Interest Coverage | -7.19 |
| Altman Z Score | -1.24 | Piotroski Score | 2 |